Edition:
United Kingdom

NuVasive Inc (NUVA.OQ)

NUVA.OQ on NASDAQ Stock Exchange Global Select Market

55.12USD
14 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$55.12
Open
$56.06
Day's High
$56.85
Day's Low
$54.81
Volume
208,754
Avg. Vol
205,345
52-wk High
$72.38
52-wk Low
$44.62

Summary

Name Age Since Current Position

Gregory Lucier

54 2018 Chairman of the Board

J. Christopher Barry

46 2018 Chief Executive Officer, Director

Rajesh Asarpota

51 2018 Principal Financial Officer, Executive Vice President, Principal Accounting Officer

Joan Stafslien

53 2016 Executive Vice President, General Counsel, Corporate Secretary

Carol Cox

53 2015 Executive Vice President - External Affairs and Corporate Marketing

Harry Kiil

43 2017 Executive Vice President, Global Commercial

Peter Leddy

54 2015 Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications

Matthew Link

43 2017 Executive Vice President - Strategy, Technology and Corporate Development

Stephen Rozow

49 2017 Executive Vice President, Global Process Transformation

Vickie Capps

56 2015 Independent Director

John DeFord

56 2018 Independent Director

Robert Friel

62 2016 Independent Director

R. Scott Huennekens

54 2018 Independent Director

Leslie Norwalk

52 2014 Independent Director

Michael O'Halleran

67 2016 Independent Director

Donald Rosenberg

66 2016 Independent Director

Daniel Wolterman

61 2015 Independent Director

Stacy Roughan

2016 Director, Investor Relations & Corporate Communications

Biographies

Name Description

Gregory Lucier

Mr. Gregory T. Lucier is Chairman of the Board of the Company. He has served as our Chairman of the Board and Chief Executive Officer since March 2015. Mr. Lucier has been a member of our Board of Directors since December 2013. Information regarding Mr. Lucier can be found above under the caption “Proposal 1 – Election of Directors — Nominees for Election of Directors and Directors Continuing in Office.”

J. Christopher Barry

Mr. J. Christopher Barry has been appointed Chief Executive Officer, Director of the Company effective November 5, 2018. He joins the Company from Medtronic plc, a global medical technology company, where he has served as Senior Vice President and President, Surgical Innovations, since January 2015. Mr. Barry joined Medtronic following its January 2015 acquisition of Covidien plc, a global healthcare technology and medical supplies provider. Mr. Barry previously spent over 15 years with Covidien in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015. Mr. Barry received a Bachelor of Science in Environmental Science from Texas Tech University.

Rajesh Asarpota

Mr. Rajesh J. Asarpota is Principal Financial Officer, Executive Vice President, Principal Accounting Officer of the Company. He Rajesh J. Asarpota has served as our Executive Vice President and Chief Financial Officer since September 2017. Mr. Asarpota has nearly 25 years of experience in financial and executive leadership roles across the healthcare industry. Mr. Asarpota began his career at General Electric, where from 1992 to 2004, he served in various finance roles, including key finance operating roles at GE Healthcare. From May 2004 to January 2014, Mr. Asarpota held a variety of senior finance roles at Life Technologies and its predecessor, Invitrogen, most recently as Vice President, Finance - Divisions, Operations, FP&A, Mergers & Acquisitions. Mr. Asarpota then joined Questcor Pharmaceuticals, a publicly-traded biopharmaceutical company, where he served as Senior Vice President, Chief Financial Officer and Principal Accounting Officer. Following the acquisition of Questcor Pharmaceuticals by Mallinckrodt in August 2014, Mr. Asarpota has held executive financial and operational roles at two private equity-backed companies, Cole-Parmer and Imaging Advantage. Mr. Asarpota served as Chief Financial Officer and Chief Operating Officer of Cole-Parmer, a global marketer, distributor and manufacturer of laboratory products, and most recently, he served as Chief Financial Officer of Imaging Advantage, a provider of radiology technology solutions.

Joan Stafslien

Ms. Joan Stafslien serves as Executive Vice President, General Counsel, Corporate Secretary of the Company. She has served as our Executive Vice President, General Counsel and Corporate Secretary since October 2016 and is responsible for leading NuVasive’s legal function. Most recently, Ms. Stafslien served as General Counsel and Corporate Secretary of CareFusion Corporation, where she led the legal team through the spin-off from Cardinal Health, Inc. in 2009 until its acquisition by Becton, Dickinson and Company in March 2015. Prior to that, Ms. Stafslien was the segment general counsel of Cardinal Health’s Clinical Technologies and Services from 2004 to 2009, joining Cardinal Health through the acquisition of Alaris Medical Systems in 2004, where she served as deputy general counsel and assistant secretary. Prior to joining Alaris, she was in private practice with Brobeck, Phleger & Harrison.

Carol Cox

Ms. Carol A. Cox is Executive Vice President - External Affairs and Corporate Marketing of the Company. She has served as the leader of NuVasive’s investor relations function since July 2014, and since August 2017, she has served as our Executive Vice President, External Affairs. Ms. Cox is responsible for leading NuVasive’s external communications efforts, which are inclusive of investor and public relations and government affairs, as well as the NuVasive Spine Foundation. Ms. Cox served as NuVasive’s Executive Vice President, External Affairs and Corporate Marketing from November 2015 to August 2017, Executive Vice President, Strategy, Corporate Development and External Affairs from July 2015 to November 2015, and Executive Vice President, Corporate Affairs and Human Resources from July 2014 to July 2015. Ms. Cox has more than 20 years of senior level experience in cross-functional corporate roles in the healthcare sector. Ms. Cox joined NuVasive in July 2014 from Sanford-Burnham Medical Research Institute where she served as Senior Vice President, External Affairs, leading external and internal communications, philanthropy, marketing, government relations and efforts to elevate the Institute’s global recognition, since March 2014. Ms. Cox previously worked for Life Technologies, a global biotechnology company, from December 2011 until its acquisition by Thermo Fisher Scientific Inc. in February 2014, most recently as Senior Vice President of External Affairs and Corporate Communications, where she spearheaded global strategies to drive awareness of the company’s major initiatives, enhance its global brand, and maintain its corporate reputation across multiple stakeholder groups including shareholders, the media, government officials, customers and the communities. Prior to joining Life Technologies, Vice President for Global Corporate Communications and Investor Relations at Barr Pharmaceuticals, where her team received multiple awards from Institutional Investor magazine for outstanding performance.

Harry Kiil

Mr. Harry Skip Kiil is Executive Vice President, Global Commercial of the company. He has served as our Executive Vice President, Global Commercial since August 2017 and is responsible for NuVasive’s global commercial strategies, including broad efforts to integrate NuVasive’s sales and service organizations. Mr. Kiil previously served as NuVasive’s Executive Vice President, International, from June 2017 to August 2017. Mr. Kiil has more than 15 years of experience as a global medical technologies and life sciences business leader. Mr. Kiil joined NuVasive from Alcon, a division of Novartis Corporation, where he most recently served as surgical head, Europe, Middle East, Africa and Russia. Prior to joining Alcon, Mr. Kiil spent more than 12 years with Stryker Corporation, most recently as vice president and general manager, Medical Surgical Group, based in London and Rome. In that capacity, he was responsible for commercial operations for six strategic business units, including Neuro Spine/ENT, Surgical Instruments, Endoscopy, Sports Medicine and General Surgery/Visualization. Previously, as a senior leader at Stryker, Mr. Kiil was general manager, MedSurg Japan, based in Tokyo. Prior to that, he had increasing corporate development, sales and marketing roles for Stryker in the United States.

Peter Leddy

Dr. Peter Michael Leddy, Ph.D., is an Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications of the Company. He has served as the leader of NuVasive’s human resources function since July 2015, as our Executive Vice President, People and Culture since August 2017 and previously as our Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications from July 2015 to August 2017. Peter M. Leddy, Ph.D. has served as the leader of NuVasive’s human resources function since July 2015, as our Executive Vice President, People and Culture since August 2017 and previously as our Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications from July 2015 to August 2017. Dr. Leddy also previously served as a member of NuVasive’s Board of Directors from 2011 to July 2015. Dr. Leddy’s success in driving business growth through the application of best-in-class, innovative human resource solutions has resulted in his leading several major employee and cultural transformation initiatives throughout his more than 30 year career. From 2005 to February 2014, Dr. Leddy served as Chief Human Resources Officer at Life Technologies, a leading, global biotechnology company. During his tenure at Life Technologies, Dr. Leddy developed a premier human resources function, aligning business strategy to business growth for 12,000 employees at over 80 sites worldwide. Prior to Life Technologies, Dr. Leddy held several senior management positions with Dell Incorporated, from 2000 to 2005, where he was responsible for leading global talent and human resources in the Americas. Dr. Leddy has held a variety of executive and human resource positions at PepsiCo. Dr. Leddy currently serves on the advisory board of the Heider College of Business at Creighton University.

Matthew Link

Mr. Matthew W. Link serves as Executive Vice President - Strategy, Technology and Corporate Development of NuVasive, Inc. He has served as our Executive Vice President, Strategy, Technology and Corporate Development since August 2017 and is responsible for leading product and systems development, global marketing, surgeon education, clinical research and corporate development. Mr. Link previously served as our President, U.S. Commercial from July 2015 to July 2017. Prior to that, he served as our President, U.S. Sales and Service from January 2015 to July 2015, Executive Vice President of U.S. Sales from January 2013 to January 2015 and Senior Vice President of Sales for the Company’s U.S. Eastern region from January 2012 to December 2012. Mr. Link joined NuVasive in 2006 and has more than 15 years in the healthcare industry serving in several regional sales positions with DePuy Orthopedics and DePuy Spine.

Stephen Rozow

Mr. Stephen Rozow serves as - Executive Vice President, Global Process Transformationof the company. He has served as our Executive Vice President, Global Process Transformation since August 2017 and is responsible for manufacturing, supply chain, information technology, regulatory affairs and quality assurance. Prior to that, Mr. Rozow served as NuVasive’s Vice President, Global Operations since April 2015. Prior to joining NuVasive, from November 2012 to April 2015, Mr. Rozow was with Rauland-Borg, most recently serving as Executive Vice President and Chief Operating Officer. Before joining Rauland-Borg, Mr. Rozow spent over 20 years with Zimmer, Inc., including senior roles in global manufacturing and operations.

Vickie Capps

Ms. Vickie L. Capps serves as Independent Director of the Company. From July 2002 to December 2013, she previously served as chief financial officer of several public and private companies. From 2002 to 2013, Ms. Capps served as the Executive Vice President, Chief Financial Officer and Treasurer at DJO Global, Inc. a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, where she was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps’ extensive financial expertise and executive leadership experience as a former chief financial officer provide valuable financial and accounting experience to our Board.

John DeFord

Dr. John A. DeFord Ph.D., is Independent Director of the company. He currently the Senior Vice President, Research and Development, Interventional Segment for Becton, Dickinson and Company, a global medical technology company. Dr. DeFord joined Becton Dickinson following its December 2017 acquisition of C.R. Bard, Inc., where he had served as Senior Vice President, Science, Technology and Clinical Affairs since June 2007. Dr. DeFord joined Bard in 2004, and served in science and technology roles of increasing responsibility since that time. Prior to joining Bard, Dr. DeFord was Managing Director of Early Stage Partners LP, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was President and CEO of Cook Incorporated, a privately held medical device manufacturer. Dr. DeFord brings valuable strategy, technology development and clinical affairs leadership experience within the medical device industry to our Board.

Robert Friel

Mr. Robert F. Friel is Independent Director of the Company. He currently the Chairman, Chief Executive Officer and President of PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment. Prior to being appointed PerkinElmer’s President and Chief Executive Officer in February 2008 and Chairman in April 2009, Mr. Friel had served as President and Chief Operating Officer since August 2007, and as Vice Chairman and President of PerkinElmer’s Life and Analytical Sciences unit since January 2006. Mr. Friel previously served as Executive Vice President and Chief Financial Officer of PerkinElmer from October 2004 until January 2006. Mr. Friel joined PerkinElmer in February 1999 as Senior Vice President and Chief Financial Officer. Prior to joining PerkinElmer, he held several senior management positions with AlliedSignal, Inc., now Honeywell International. Mr. Friel’s experience as the Chief Executive Officer and President of PerkinElmer, as well as his experience as a former chief financial officer, provide valuable leadership and financial experience to our Board.

R. Scott Huennekens

Mr. R. Scott Huennekens is Independent Director of the Company. He has served as President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform, since August 2015. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider. Mr. Huennekens currently serves on the Board of Directors of ViewRay Inc., and he previously served on the Board of Directors of Reva Medical Inc. and Endochoice Holdings, Inc. Mr. Huennekens is a member of the Board of Directors and past Chairman of the Medical Device Manufacturers Association (MDMA), a national trade association. Mr. Huennekens holds a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School.

Leslie Norwalk

Ms. Leslie V. Norwalk, Esq., is Independent Director of the Company. She currently Strategic Counsel to Epstein Becker & Green, P.C., EBG Advisors and National Health Advisors. She also serves as an advisor to private equity firms Warburg Pincus, Peloton Equity, and Enhanced Equity Fund. Ms. Norwalk previously served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency’s Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, she practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative. Ms. Norwalk currently sits on the boards of directors of several private companies, and she is a member of APCO Worldwide’s International Advisory Council. Ms. Norwalk’s deep knowledge of, and experience with, the healthcare industry and government regulations provides valuable guidance and insight to our Board.

Michael O'Halleran

Mr. Michael D. O'Halleran is an Independent Director of the Company. currently a special advisor to ManchesterStory Group and as chair of the advisory board of the ManchesterStory Venture Fund L.P. Mr. O’Halleran previously served as the Executive Chairman of Aon Benfield and Senior Executive Vice President of Aon plc, a provider of risk management, insurance and consulting service. Mr. O’Halleran joined the Aon group of companies in 1987 to lead its reinsurance division and since that time, served in several significant management positions including President and Chief Operating Officer of Aon Corp., and since August 2007 until his retirement in May 2017, as the Executive Chairman of Aon Benfield. Prior to joining Aon, he was a senior executive with well-known companies in the insurance industry. Mr. O’Halleran’s deep knowledge of the insurance industry and his many years of executive and board leadership experience, including his experience serving on the boards of companies in the healthcare industry, make Mr. O’Halleran a valuable member of our Board.

Donald Rosenberg

Mr. Donald J. Rosenberg, J.D., is Independent Director of the Company. He currently the Executive Vice President, General Counsel and Corporate Secretary of Qualcomm Incorporated, a world leader in 3G, 4G and next-generation wireless technologies. Prior to joining Qualcomm in October 2007, Mr. Rosenberg served as Senior Vice President, General Counsel and Corporate Secretary of Apple Inc. since December 2006. From May 1975 to November 2006, Mr. Rosenberg held numerous positions at IBM Corporation, including Senior Vice President and General Counsel. Mr. Rosenberg has served as an adjunct professor of law at New York’s Pace University School of Law, where he taught courses in intellectual property and antitrust law. Mr. Rosenberg brings significant experience in legal and compliance matters, as well as global leadership experience, to our Board.

Daniel Wolterman

Mr. Daniel J. Wolterman is Independent Director of the Company. He currently the Chief Executive Officer of ColubrisMX, Inc. and X-Cath, Inc., both privately-held medical device companies that he joined in January 2018. Mr. Wolterman previously served as President and Chief Executive Officer of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in 2016. He has more than 30 years of experience in the healthcare industry and a long history of community involvement. Mr. Wolterman’s extensive knowledge of the healthcare industry and his executive leadership experience as President and CEO of Memorial Hermann Health System provide valuable perspective and guidance to the Board.

Stacy Roughan